{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in tumors.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        }
      ],
      "caveat": "This report summarizes normalized scores but does not provide full experimental details or variability; mechanistic readouts were not uniformly strongest across all settings."
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination broadens antigen processing/presentation and expands the MHC-I peptidome.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        },
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        },
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        }
      ],
      "caveat": "The summary provides fractions of proteins represented but does not specify which tumor models or technical parameters drove the changes, limiting generalizability."
    },
    {
      "claim_id": "C03",
      "claim": "Intratumoral mRNA vaccination increases PD-L1 pathway activity, supporting combination with checkpoint blockade.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        },
        {
          "quote": "| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |",
          "line_ref": "L32"
        }
      ],
      "caveat": "Increased PD-L1 expression can reflect inflammatory signaling and does not by itself prove improved clinical benefit without direct outcome data in controlled settings."
    },
    {
      "claim_id": "C04",
      "claim": "The combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        }
      ],
      "caveat": "The human evidence is retrospective and non-randomized with heterogeneous timing and tumor types, so association cannot establish causality."
    },
    {
      "claim_id": "C05",
      "claim": "Type I interferon signaling is required for the sensitization effect, and non-mRNA lipid particle controls do not reproduce it.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "- Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        },
        {
          "quote": "- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "These are summarized control statements without effect sizes; the report does not quantify the degree of elimination or whether alternative pathways contribute."
    }
  ]
}